Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Mammary Neoplasms, Human”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Looking for participantsNCT04836156
What this trial is testing

Neoadjuvant Therapy Study Guided by Drug Screening in Vitro for Human Epidermal Growth Factor Receptor 2 (HER2) Negative Early Breast Cancer Patients

Who this might be right for
HER2-negative Early Breast Cancer
Peking University People's Hospital 46
Not applicableUnknownNCT01779531
What this trial is testing

Compare the Outcomes of XT and XEC Adjuvant Chemotherapy in HER2-negative Luminal B Breast Cancer Patients

Who this might be right for
Human Epidermal Growth Factor 2 Negative Carcinoma of Breast
Guangdong Academy of Medical Sciences 640
Large-scale testing (Phase 3)Active Not RecruitingNCT05365178
What this trial is testing

To Evaluate the Efficacy and Safety of TQB3616 in Combination With Fulvestrant Versus Placebo in Combination With Fulvestrant in Previously Untreated Hormone-receptor (HR)-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Advanced Breast Cancer

Who this might be right for
HR-positive, HER2-negative Breast Neoplasms
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. 432
Large-scale testing (Phase 3)Active Not RecruitingNCT04915755
What this trial is testing

Efficacy and Safety Comparison of Niraparib to Placebo in Participants With Human Epidermal Growth Factor 2 Negative (HER2-) Breast Cancer Susceptibility Gene Mutation (BRCAmut) or Triple-Negative Breast Cancer (TNBC) With Molecular Disease

Who this might be right for
Neoplasms, Breast
GlaxoSmithKline 40
Not applicableStudy completedNCT00001898
What this trial is testing

Microarray Analysis for Human Genetic Disease

Who this might be right for
Breast NeoplasmHereditary Neoplastic SyndromeMelanoma+1 more
National Human Genome Research Institute (NHGRI) 1,500
Testing effectiveness (Phase 2)Ended earlyNCT04172597
What this trial is testing

Poziotinib in Patients With Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Activating Mutations in Advanced Malignancies

Who this might be right for
Breast CancerColorectal CancerSolid Tumor+1 more
Spectrum Pharmaceuticals, Inc 1
Early research (Phase 1)Study completedNCT02060253
What this trial is testing

Ganetespib, Paclitaxel, Trastuzumab and Pertuzumab for Metastatic Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer

Who this might be right for
HER2-positive Breast CancerMale Breast CancerRecurrent Breast Cancer+4 more
Memorial Sloan Kettering Cancer Center 9
Large-scale testing (Phase 3)Not Yet RecruitingNCT06996093
What this trial is testing

Chemotherapy Omission in HR-positive/HER2-negative Breast Cancer With Lymph Node Negative Disease Receiving Adjuvant Endocrine Therapy and CDK4/6 Inhibitor

Who this might be right for
Breast Cancer
Fudan University 2,508
Testing effectiveness (Phase 2)Study completedNCT03310957
What this trial is testing

Safety and Efficacy of SGN-LIV1A Plus Pembrolizumab for Patients With Locally-Advanced or Metastatic Triple-Negative Breast Cancer

Who this might be right for
Triple Negative Breast Neoplasms
Seagen Inc. 185
Testing effectiveness (Phase 2)Ended earlyNCT01131364
What this trial is testing

Combination Therapy of F16IL2 and Doxorubicin in Solid Tumour Patients

Who this might be right for
Advanced Solid TumorBreast Cancer
Philogen S.p.A. 29
Not applicableStudy completedNCT04807595
What this trial is testing

Estimation of the Prevalence of HER2 Low and Describe the SoC, Treatment Patterns, and Outcome in Real-world Practice Among Unresectable and/or Metastatic Breast Cancer Patients With HER2 Low Status

Who this might be right for
Breast Cancer
AstraZeneca 798
Testing effectiveness (Phase 2)Looking for participantsNCT06964906
What this trial is testing

Neoadjuvant High-Intensity Focused Ultrasound (HIFU) Combined With Toripalimab and Chemotherapy for ER-Positive /HER2-Negative Breast Cancer

Who this might be right for
ER+/HER2- Breast Cancer
Second Affiliated Hospital, Zhejiang University, School of Medicine 30
Testing effectiveness (Phase 2)Looking for participantsNCT05748834
What this trial is testing

Study of Tucatinib and Doxil in Participants With Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer

Who this might be right for
Breast Cancer
SCRI Development Innovations, LLC 36
Not applicableStudy completedNCT05153187
What this trial is testing

Real-world Treatment Patterns of Endocrine Based Therapy Among Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor-2-negative (HR+/HER2-) Advanced Breast Cancer: An Analysis of Administrative Claims Data in Japan

Who this might be right for
Breast Cancer
Pfizer 1,170
Large-scale testing (Phase 3)Study completedNCT02896855
What this trial is testing

Evaluate the Efficacy and Safety of Pertuzumab + Trastuzumab + Docetaxel Versus Placebo + Trastuzumab + Docetaxel in Previously Untreated Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Hoffmann-La Roche 243
Large-scale testing (Phase 3)Study completedNCT00045032
What this trial is testing

Herceptin (Trastuzumab) in Treating Women With Human Epidermal Growth Factor Receptor (HER) 2-Positive Primary Breast Cancer

Who this might be right for
Breast Cancer
Hoffmann-La Roche 5,099
Large-scale testing (Phase 3)Active Not RecruitingNCT04895358
What this trial is testing

Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49)

Who this might be right for
Breast Neoplasms
Merck Sharp & Dohme LLC 342
Early research (Phase 1)Study completedNCT00920257
What this trial is testing

A Phase I, Open-Label, First-Time-In-Human Study of the Oral AKT Inhibitor GSK2141795

Who this might be right for
Cancer
GlaxoSmithKline 77
Early research (Phase 1)Study completedNCT03219268
What this trial is testing

MGD013 in Patients With Unresectable or Metastatic Neoplasms

Who this might be right for
Advanced Solid TumorsHematologic NeoplasmsOvarian Cancer+7 more
MacroGenics 277
Not applicableEnded earlyNCT00700778
What this trial is testing

Recombinant Human Chorionic Gonadotropin in Preventing Breast Cancer in Premenopausal Women With BRCA1 Mutations

Who this might be right for
BRCA1 MutationBreast Cancer
Fox Chase Cancer Center 2
Next Page